Clinical Significance of High C-MYC and Low MYCBP2 Expression and Their Association with Ikaros Dysfunction in Adult Acute Lymphoblastic Leukemia

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Oct 31

PMID 26517351

Citations 27

Authors

Zheng Ge

Xing Guo

Jianyong Li

Melanie Hartman

Yuka Imamura Kawasawa

Sinisa Dovat

Chunhua Song

Affiliations

Soon will be listed here.

Abstract

Increased expression of c-MYC is observed in both Acute Myeloid Leukemia (AML) and T-cell Acute Lymphoblastic Leukemia (T-ALL). MYC binding protein 2 (MYCBP2) is a probable E3 ubiquitin ligase and its function in leukemia is unknown. IKZF1 deletion is associated with the development and poor outcome of ALL. Here, we observed significant high c-MYC expression and low MYCBP2 expression in adult ALL patients. Patients with high c-MYC expression and/or low MYCBP2 expression had higher WBC counts and a higher percentage of CD34+ or CD33+ cells, as well as splenomegaly, liver infiltration, higher BM blasts, and lower CR rate. Ikaros bound to the regulatory regions of c-MYC and MYCBP2, suppressed c-MYC and increased MYCBP2 expression in ALL cells. Expression of c-MYC mRNA was significantly higher in patients with IKZF1 deletion; conversely MYCBP2 mRNA expression was significantly lower in those patients. A CK2 inhibitor, which acts as an Ikaros activator, also suppressed c-MYC and increased MYCBP2 expression in an Ikaros (IKZF1) dependent manner in the ALL cells. In summary, our data indicated the correlation of high c-MYC expression, low MYCBP2 expression and high c-MYC plus low MYCBP2 expression with high-risk factors and proliferation markers in adult ALL patients. Our data also revealed an oncogenic role for an Ikaros/MYCBP2/c-MYC axis in adult ALL, providing a mechanism of target therapies that activate Ikaros in adult ALL.

Citing Articles

Characterization of , and Expression in Biological Subgroups of Children with Acute Lymphoblastic Leukemia.

Lo Nigro L, Arrabito M, Andriano N, Iachelli V, La Rosa M, Bonaccorso P Int J Mol Sci. 2025; 26(3).

PMID: 39940843 PMC: 11817342. DOI: 10.3390/ijms26031076.

Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.

Safa F, Rasmussen T, Fontan L, Xia M, Melnick A, Wiestner A Haematologica. 2023; 109(5):1348-1358.

PMID: 37767562 PMC: 11063839. DOI: 10.3324/haematol.2023.283178.

Dysfunction of ubiquitin protein ligase leads to cell resilience in human breast cancers.

Neff R, Bosch-Gutierrez A, Sun Y, Katsyv I, Song W, Wang M NAR Cancer. 2023; 5(3):zcad036.

PMID: 37435531 PMC: 10331931. DOI: 10.1093/narcan/zcad036.

IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?.

Conserva M, Redavid I, Anelli L, Zagaria A, Tarantini F, Cumbo C Int J Mol Sci. 2023; 24(4).

PMID: 36834692 PMC: 9961161. DOI: 10.3390/ijms24043282.

MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.

Wang G, Miao C, Mo L, Kahlert U, Wu J, Ou M Front Immunol. 2022; 13:1048503.

PMID: 36582246 PMC: 9792662. DOI: 10.3389/fimmu.2022.1048503.

References

Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P . Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008; 22(5):915-31. DOI: 10.1038/leu.2008.19. View

Pereira-Fernandes A, Dirinck E, Dirtu A, Malarvannan G, Covaci A, Van Gaal L . Expression of obesity markers and Persistent Organic Pollutants levels in adipose tissue of obese patients: reinforcing the obesogen hypothesis?. PLoS One. 2014; 9(1):e84816. PMC: 3888404. DOI: 10.1371/journal.pone.0084816. View

Li Z, Song C, Ouyang H, Lai L, Payne K, Dovat S . Cell cycle-specific function of Ikaros in human leukemia. Pediatr Blood Cancer. 2011; 59(1):69-76. PMC: 3292658. DOI: 10.1002/pbc.23406. View

Kang H, Chen I, Wilson C, Bedrick E, Harvey R, Atlas S . Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood. 2009; 115(7):1394-405. PMC: 2826761. DOI: 10.1182/blood-2009-05-218560. View

Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S . Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010; 115(14):2845-51. PMC: 2854430. DOI: 10.1182/blood-2009-07-234377. View

Guo X, Zhang R, Liu J, Li M, Song C, Dovat S . Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia. PLoS One. 2015; 10(5):e0125429. PMC: 4420493. DOI: 10.1371/journal.pone.0125429. View

Adhikary S, Eilers M . Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6(8):635-45. DOI: 10.1038/nrm1703. View

Grabher C, von Boehmer H, Look A . Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006; 6(5):347-59. DOI: 10.1038/nrc1880. View

Harvey R, Mullighan C, Wang X, Dobbin K, Davidson G, Bedrick E . Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010; 116(23):4874-84. PMC: 3321747. DOI: 10.1182/blood-2009-08-239681. View

10.

Wang H, Ouyang H, Lai L, Petrovic-Dovat L, Stankov K, Bogdanovic G . Pathogenesis and regulation of cellular proliferation in acute lymphoblastic leukemia - the role of Ikaros. J BUON. 2014; 19(1):22-8. View

11.

Rice K, Hormaeche I, Doulatov S, Flatow J, Grimwade D, Mills K . Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood. 2009; 114(27):5499-511. PMC: 2798864. DOI: 10.1182/blood-2009-03-206524. View

12.

Faderl S, OBrien S, Pui C, Stock W, Wetzler M, Hoelzer D . Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010; 116(5):1165-76. PMC: 5345568. DOI: 10.1002/cncr.24862. View

13.

Prins R, Burke R, Tyner J, Druker B, Loriaux M, Spurgeon S . CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013; 27(10):2094-6. DOI: 10.1038/leu.2013.228. View

14.

Brown K, Guest S, Smale S, Hahm K, MERKENSCHLAGER M, Fisher A . Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin. Cell. 1997; 91(6):845-54. DOI: 10.1016/s0092-8674(00)80472-9. View

15.

Hoffman B, Amanullah A, Shafarenko M, Liebermann D . The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene. 2002; 21(21):3414-21. DOI: 10.1038/sj.onc.1205400. View

16.

Cardone M, Kandilci A, Carella C, Nilsson J, Brennan J, Sirma S . The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol Cell Biol. 2005; 25(6):2395-405. PMC: 1061619. DOI: 10.1128/MCB.25.6.2395-2405.2005. View

17.

Weng A, Millholland J, Yashiro-Ohtani Y, Arcangeli M, Lau A, Wai C . c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006; 20(15):2096-109. PMC: 1536060. DOI: 10.1101/gad.1450406. View

18.

Gilliland D, Griffin J . The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002; 100(5):1532-42. DOI: 10.1182/blood-2002-02-0492. View

19.

Guo Q, Xie J, Dang C, Liu E, Bishop J . Identification of a large Myc-binding protein that contains RCC1-like repeats. Proc Natl Acad Sci U S A. 1998; 95(16):9172-7. PMC: 21311. DOI: 10.1073/pnas.95.16.9172. View

20.

Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S . Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 2004; 24(7):2890-904. PMC: 371102. DOI: 10.1128/MCB.24.7.2890-2904.2004. View